New combination vaccines: DTaP-IPV (kinrix) and DTaP-IPV/Hib (pentacel)

Annals of Pharmacotherapy

Volumn 44, Issue 3, 2010, Pages 515-523

  Johns, Tracy L ^a,b   Hutter, George E ^a,b  

^a MORTON PLANT MEASE HEALTH CARE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Combination vaccines; DTaP; Hib; IPV; Kinrix; Pentacel

Indexed keywords

BACTERIAL VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; KINRIX; MEASLES MUMPS RUBELLA VACCINE; PENTACEL; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT HEPATITIS B VACCINE; TRIHIBIT; UNCLASSIFIED DRUG;

ANTIBODY TITER; CHILD; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIPHTHERIA; DRUG COST; DRUG FEVER; DRUG LABELING; DRUG PACKAGING; DRUG SAFETY; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; INFLUENZA; INFORMATION RETRIEVAL; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MEDLINE; PASSIVE IMMUNIZATION; PATIENT COUNSELING; PERTUSSIS; POLIOMYELITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVACCINATION; REVIEW; SERODIAGNOSIS; TETANUS;

CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; POLIOVIRUS VACCINE, INACTIVATED; VACCINES, COMBINED;

EID: 77749329721     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M468     Document Type: Review

References (37)

1. Combination vaccines for childhood immunization. MMWR Recomm Rep 1999;48:1-14.
2. Pierce VM, Vazquez M. New combination vaccines: integration into pediatric practice. Pediatr Infect Dis J 2007;26:1149-50.
3. Marshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007;26:496-500.
4. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006;25:507-12.
5. Happe LE, Lunacsek OE, Marshall GS, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care 2007;13:506-12.
6. Haemophilus influenzae infections. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2006:310-8.
7. Product information. Kinrix (diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine). Research Triangle Park, NC: GlaxoSmithKline, March 2009.
8. Weston WM, Klein NP. Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years. Expert Rev Vaccines 2008;7:1309-20.
9. Product information. Pentacel (diphtheria and tetanus toxoid and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b conjugate (tetanus toxoid conjugate) vaccine). Swiftwater, PA: Sanofi Pasteur, June 2008.
10. Black S, Greenberg DP. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine. Expert Rev Vaccines 2005;4:793-805.
11. Black S, Friedland LR, Schuind A, Howe B. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years. Vaccine 2006;24:6163-71.
12. Marshall H, Nolan T, Roberton D, et al. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years. Vaccine 2006;24:6120-8.
13. Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Pediatr Infect Dis J 2008;27:341-6.
14. Nilsson L, Faldella G, Jacquet JM, Storsaeter J, Silfverdal SA, Ekholm L. A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age. Scand J Infect Dis 2005;37:221-9.
15. Jacquet JM, Begue P, Grimprel E, et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. Vaccine 2006;24:2440-8.
16. Mills E, Gold R, Thipphawong J, et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus B conjugate vaccine administered to infants at two, four and six months of age. Vaccine 1998;16:576-85.
17. Guerra FA, Blatter MM, Greenberg DP, Pichichero M, Noriega FR. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics 2009;123:301-12.
18. Scheifele DW, Halperin SA, Rubin E, et al. Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and Haemophilus influenzae type B conjugate) when administered as a fourth dose at 15 to 18 months of age. Hum Vaccine 2005;1:180-6.
19. Edwards K TP, Wang L, et al. Safety and immunogenicity of DTaP-IPV//PRP-T (Pentacel) coadministered with pneumococcal conjugate vaccine (Prevnar) at 2, 4, and 6 months of age (abstract 984). Presented at: 43rd Annual Meeting, Infectious Disease Society of America, 2005.
20. Scheifele DW, Halperin SA, Smith B, Ochnio J, Meloff K, Duarte-Monteiro D. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age. Vaccine 2006;24:2057-64.
21. Food and Drug Administration. Center for Biologics Evaluation and Research. Guidance for industry for the evaluation of combination vaccines for preventable diseases: production, testing and clincal studies. April 1997. www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM175909.pdf (accessed 2009 Nov 3).
22. Eskola J, Olander RM, Hovi T, Litmanen L, Peltola S, Kayhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996;348:1688-92.
23. Lee CY, Thipphawong J, Huang LM, et al. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics 1999;103:25-30.
24. Schmitt HJ, von Kries R, Hassenpflug B, et al. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr Infect Dis J 2001;20:767-74.
25. Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. MMWR Morb Mortal Wkly Rep 2009;58:1008-9.
26. Greenberg DP, Pickering LK, Senders SD, et al. Interchangeability of 2 diphtheria-tetanus-acellular pertussis vaccines in infancy. Pediatrics 2002;109:666-72.
27. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55.
28. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997;350:1569-77.
29. Centers for Disease Control and Prevention. ACIP provisional recommendations for the use of combination vaccines: August 2009. www.cdc.gov/vaccines/recs/provisional/default.htm (accessed 2009 Oct 19).
30. Centers for Disease Control and Prevention. Guidance on the use of Pentacel and Pediarix: August 2008. www.cdc.gov/vaccines/vpd-vac/hib/downloads/ pentacel-guidance-508.pdf (accessed 2009 Jun 5).
31. Updated recommendations for use of Haemophilus influenzae type b (Hib): reinstatement of the booster dose at ages 12-15 months. MMWR Morb Mortal Wkly Rep 2009;58:673-4.
32. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children. MMWR Morb Mortal Wkly Rep 2008;57:1079-80.
33. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR Morb Mortal Wkly Rep 2008;57:1078-9.
34. Product information. Pediarix (diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis b (recombinant), and inactivated poliovirus vaccine combined). Research Triangle Park, NC: GlaxoSmithKline, July 2009.
35. Centers for Disease Control and Prevention. Atkinson W, Wolfe S, Hamborsky J, McIntyre L, eds. Epidemiology and prevention of vaccine-preventable diseases. 11th ed. Washington, DC: Public Health Foundation, 2009.
36. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep 2009;58:829-30.
37. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years-United States, 2009. MMWR Morb Mortal Wkly Rep 2009;57(51&52).M468 CE